Nektar Therapeutics (Nasdaq: NKTR) announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer… Read Full Article

Cell Therapeutics, Inc. (“CTI”) (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI’s OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue… Read Full Article

A study of electronic patient records, funded by the Wellcome Trust, suggests that older women with suspected ovarian cancer may be referred by their GPs for investigation later than younger women… Read Full Article

A study of electronic patient records, funded by the Wellcome Trust, suggests that older women with suspected ovarian cancer may be referred by their GPs for investigation later than younger women… Read Full Article

Moved by the death of an employee’s daughter, prominent international businessman and philanthropist Foster Friess will make a substantial contribution to fund ovarian cancer research at the Translational Genomics Research Institute (TGen)… Read Full Article

Moved by the death of an employee’s daughter, prominent international businessman and philanthropist Foster Friess will make a substantial contribution to fund ovarian cancer research at the Translational Genomics Research Institute (TGen)… Read Full Article

An imaging technique combining ultrasound and specially modified contrast agents may allow researchers to noninvasively detect cancer and show its progression, according to research published in the March issue of The Journal of Nuclear Medicine (JNM). The technique enables researchers to visualize tumor activity at the molecular level… Read Full Article

An imaging technique combining ultrasound and specially modified contrast agents may allow researchers to noninvasively detect cancer and show its progression, according to research published in the March issue of The Journal of Nuclear Medicine (JNM). The technique enables researchers to visualize tumor activity at the molecular level… Read Full Article

2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical… Read Full Article

Huixin He, associate professor of nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that could potentially eliminate the problems of side effects and drug resistance in the treatment of cancer… Read Full Article